PMC:7247521 / 1049-1442 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"29","span":{"begin":99,"end":105},"obj":"Gene"},{"id":"30","span":{"begin":116,"end":120},"obj":"Gene"},{"id":"31","span":{"begin":207,"end":211},"obj":"Gene"},{"id":"38","span":{"begin":367,"end":372},"obj":"Chemical"},{"id":"41","span":{"begin":15,"end":36},"obj":"Disease"},{"id":"42","span":{"begin":38,"end":44},"obj":"Disease"},{"id":"43","span":{"begin":46,"end":83},"obj":"Disease"},{"id":"44","span":{"begin":193,"end":202},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:406959"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:1022"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Gene:59272"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D007249"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D001249"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D029424"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":66,"end":75},"obj":"UBERON:0002048"},{"id":"T24","span":{"begin":92,"end":97},"obj":"SO:0000276"},{"id":"T25","span":{"begin":116,"end":120},"obj":"PR:000005265"},{"id":"T26","span":{"begin":207,"end":211},"obj":"G_3;PG_10;PR:000003622"},{"id":"T27","span":{"begin":215,"end":225},"obj":"GO:0010467"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":226,"end":234},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":15,"end":36},"obj":"Disease"},{"id":"T7","span":{"begin":38,"end":44},"obj":"Disease"},{"id":"T8","span":{"begin":46,"end":83},"obj":"Disease"},{"id":"T9","span":{"begin":193,"end":202},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":334,"end":340},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":126,"end":128},"obj":"Chemical"},{"id":"T6","span":{"begin":226,"end":234},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_74862"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":38,"end":44},"obj":"Phenotype"},{"id":"T2","span":{"begin":46,"end":83},"obj":"Phenotype"},{"id":"T3","span":{"begin":193,"end":202},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T15","span":{"begin":126,"end":128},"obj":"http://purl.obolibrary.org/obo/GO_0000981"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":136,"end":235},"obj":"Sentence"},{"id":"T14","span":{"begin":236,"end":353},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"eases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed t"}